Department of Infectious Diseases
Sharon R. Lewin has not added Biography.
If you are Sharon R. Lewin and would like to personalize this page please email our Author Liaison for assistance.
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.
PLoS pathogens Jul, 2015 | Pubmed ID: 26133551
HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV.
BMC infectious diseases Mar, 2016 | Pubmed ID: 26945746
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.
AIDS (London, England) 05, 2017 | Pubmed ID: 28301423
Editorial: HIV and lipopolysaccharide: double trouble in the liver.
Journal of leukocyte biology 05, 2017 | Pubmed ID: 28468986
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?
Journal of virology 12, 2017 | Pubmed ID: 29021399
Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
Cell host & microbe Jan, 2018 | Pubmed ID: 29324227
The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
The lancet. HIV 05, 2018 | Pubmed ID: 29643011
The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Journal of virology 07, 2018 | Pubmed ID: 29643247
Barriers and strategies to achieve a cure for HIV.
The lancet. HIV 06, 2018 | Pubmed ID: 29893245
Strategies for an HIV cure: progress and challenges.
Nature immunology 11, 2018 | Pubmed ID: 30333614
Functional cure of HIV: the scale of the challenge.
Nature reviews. Immunology 01, 2019 | Pubmed ID: 30410126
Between a shock and a hard place: challenges and developments in HIV latency reversal.
Current opinion in virology 10, 2019 | Pubmed ID: 31048093
CD4 T cell signatures in HIV infection.
Nature immunology 08, 2019 | Pubmed ID: 31308542
Tesamorelin, liver fat, and NAFLD in the setting of HIV.
The lancet. HIV 12, 2019 | Pubmed ID: 31611037
CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4 T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained.
Journal of virology 02, 2020 | Pubmed ID: 31852784
Limitations of dual-fluorescent HIV reporter viruses in a model of pre-activation latency.
Journal of the International AIDS Society 12, 2019 | Pubmed ID: 31855322
Combination Immune Checkpoint Blockade to Reverse HIV Latency.
Journal of immunology (Baltimore, Md. : 1950) 03, 2020 | Pubmed ID: 31988180
Kick and kill for HIV latency.
Lancet (London, England) 03, 2020 | Pubmed ID: 32085822
A cure for HIV: how would we know?
The lancet. HIV 05, 2020 | Pubmed ID: 32169159
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.
Nature medicine 04, 2020 | Pubmed ID: 32284614
Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting.
The Journal of infectious diseases 09, 2020 | Pubmed ID: 32761124
Leveraging the advances in HIV for COVID-19.
Lancet (London, England) 10, 2020 | Pubmed ID: 33010825
Multi-stakeholder consensus on a target product profile for an HIV cure.
The lancet. HIV 01, 2021 | Pubmed ID: 33271125
Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.
EBioMedicine Mar, 2021 | Pubmed ID: 33647768
The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy.
AIDS (London, England) 08, 2021 | Pubmed ID: 33859108
Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study.
The Lancet regional health. Western Pacific Apr, 2021 | Pubmed ID: 33937887
The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency.
Frontiers in genetics , 2021 | Pubmed ID: 34194479
Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance.
Nature communications 07, 2021 | Pubmed ID: 34257311
Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.
Nature communications 07, 2021 | Pubmed ID: 34272399
Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy.
The Journal of infectious diseases 05, 2022 | Pubmed ID: 34655216
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.
Nature medicine 12, 2021 | Pubmed ID: 34848888
Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.
Journal of immunology (Baltimore, Md. : 1950) 01, 2022 | Pubmed ID: 34853078
Immune checkpoint blockade in HIV.
EBioMedicine Feb, 2022 | Pubmed ID: 35123267
Nanoscale probing and imaging of HIV-1 RNA in cells with a chimeric LNA-DNA sensor.
Nanoscale Feb, 2022 | Pubmed ID: 35142755
Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Apr, 2022 | Pubmed ID: 35396591
Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.
Frontiers in cellular and infection microbiology , 2022 | Pubmed ID: 35573784
Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR).
Pathology Aug, 2022 | Pubmed ID: 35778288
Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART.
Annals of neurology Oct, 2022 | Pubmed ID: 35867351
The role of latency reversal in HIV cure strategies.
Journal of medical primatology Oct, 2022 | Pubmed ID: 36029233
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
Clinical pharmacokinetics Aug, 2022 | Pubmed ID: 36040613
1Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity,
2Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity,
3Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity,
4Department of Infectious Diseases, Alfred Hospital and Monash University,
5Department of Chemical Engineering, The University of Melbourne,
6Department of Biomedical Engineering, The University of Melbourne
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved